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Strengths and limitations of this study
 ► A strength of this study was recruitment of a diverse 
sample of general practitioners (GPs), with experi-
ence ranging from less than 5 years to more than 
25 years, practising in a range of urban and rural 
population practices.
 ► Multiple coders from different professional back-
grounds supported a more complex understanding 
of the phenomenon and a greater reflexivity in data 
analysis.
 ► While data saturation was reached, theoretical sat-
uration and theory development were not within the 
scope of the study.
 ► The sample of GPs was affiliated to one country and 
participants were from a network of GP tutors who 
may have enhanced knowledge of deprescribing.
 ► Our study highlights the need for access to de-
tailed professional guidance on tapering additional 
research on rates of relapse among patients on 
long- term antidepressant use and those discontin-
ued from antidepressants and improved access to 
psychological supports to facilitate deprescribing.
AbStrACt
Objective Our aim was to explore general practitioners’ 
(GPs) perceptions and experiences of discontinuing 
antidepressants.
Study design A qualitative study using semistructured 
interviews was undertaken between July 2019 and March 
2020. The interviews were transcribed and analysed using 
a thematic analysis framework.
Setting GPs affiliated with a university education and 
research network for general practice in Ireland.
Participants A purposive sample of GPs (n=10).
results Five themes emerged: shared decision- making; 
personalised therapy; medication- tapering toolkit; health 
service factors and concerns around tapering. GPs 
described being less likely to engage in deprescribing 
for patients with long- term and/or recurrent depression, 
older patients and those with comorbidities due to fear 
of relapse. Access to evidence- based psychological 
therapies, guidelines, information on rates of relapse, 
patient leaflets on discontinuing antidepressants and 
reminder prompts on GP- prescribing software were 
suggested to optimise appropriate antidepressant 
discontinuation. There was some suggestion that patients 
may use antidepressants for longer when talk therapy is 
not available or taken up.
Conclusions GPs are largely confident in their role of 
managing mild- to- moderate depression and deprescribing 
antidepressants. This study provides an insight into 
factors that influence GPs’ decisions to deprescribe 
antidepressants. More information on rates of relapse 
after discontinuation would be helpful to inform decision- 
making.
IntrOduCtIOn
In 2015, Ireland’s most recent census identi-
fied that 8% of residents reported attending 
consultations for moderate- to- severe depres-
sion in the past 2 weeks.1 Similarly, the preva-
lence of depression in the UK is reported to 
be 9.9%.2 In Ireland, and internationally, the 
majority of cases of depression are managed 
in the community by general practitioners 
(GPs).3–5 Antidepressant drugs such as selec-
tive serotonin reuptake inhibitors (SSRIs) 
and serotonin norepinephrine reuptake 
inhibitors (SNRIs) are frequently prescribed 
as part of a broader treatment plan involving 
psychological therapy, exercise and other 
non- pharmacological treatments. Antidepres-
sants are generally recommended as first- line 
treatment in patients whose depression is 
of at least moderate severity.6 Of this group, 
approximately 50% will respond to antide-
pressant drug therapy.6
It is recommended that patients taking anti-
depressants be regularly reviewed to monitor 
how well the treatment is working, adherence, 
side effects, as well as to ensure that long- term 
use remains clinically indicated.7 The normal 
course of antidepressant treatment should 
last at least 6 months after full symptom remis-
sion. In patients with a history of recurrent 
depression or those who are at higher risk 
of relapse, antidepressant treatment should 
continue for at least 2 years. Continued main-
tenance therapy is only indicated in patients 
with a history of severe depression (eg, suicide 
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attempt), chronic episodes (episode >2 years), a strong 
family history or highly recurrent major depression.8 
Despite these guidelines, an increase in long- term anti-
depressant use (beyond 2 years) has been observed with 
SSRIs and SNRIs in several international epidemiological 
studies.9–11 While there is evidence that antidepressants 
particularly SSRIs can help in chronic depression,12 13 
there is also evidence of ineffectiveness and harmful side 
effects, particularly with long- term use.14–16
Deprescribing of antidepressants should be considered 
after 6 months of full symptom remission.17 Deprescribing 
is the planned and supervised process of dose reduction 
or stopping of medication that might be causing harm 
or might no longer be providing benefit.18 The goal 
of deprescribing is to reduce medication burden and 
harm while maintaining or improving quality of life 
which aligns with the National Patient Safety Strategy 
2019–2024.19 While some people need antidepressants 
to prevent relapse/recurrence, 30%–50% of long- term 
users have no evidence- based indication to continue 
their medication.4 9 20 Deprescribing typically takes place 
during medication reviews. There is currently no stan-
dardised approach to medication reviews in Ireland. The 
National Medicines Management programme in Ireland 
has one deprescribing guidance document for benzodiaz-
epines. Current UK guidelines suggest when stopping an 
antidepressant, gradually reduce the dose over a 4- week 
period.17 Beyond that, detailed professional- approved 
guidelines for GPs on tapering and discontinuing antide-
pressants are not available.
Few researchers have explored GPs’ views and experi-
ences of deprescribing antidepressants.18 21 22 The issues 
of risk of relapse, personal circumstances of the patients, 
expectations on responsibility for initiating discontinu-
ation and organisational constraints of general practice 
have previously been identified as factors that influence 
deprescribing decisions.18 21 22 Furthermore, a recent 
systematic review concluded that further research is 
required to explore GPs’ perspectives on antidepressant 
discontinuation as an understanding of GPs’ views may 
support the development of safe and effective approaches 
to deprescribing antidepressants.18
This study sets out to qualitatively explore GPs’ percep-
tions and involvement in discontinuing antidepressant 
use. To our knowledge, this is the first study to investi-
gate GPs’ role in deprescribing in the Irish context. 
Understanding deprescribing processes in primary care 
is an important step in designing policy initiatives and 
healthcare systems to optimise appropriate antidepres-
sant discontinuation. The reporting of this study was 
informed by Consolidated criteria for Reporting Qualita-
tive research criteria.23
MethOdS
An exploratory qualitative design was chosen for this study 
as its emphasis on the environment, meaning and expe-
rience was considered appropriate to enable researchers 
to gain an in- depth understanding of participants’ expe-
riences and clinical decision- making in relation to discon-
tinuing antidepressants in primary care.24
Purposive sampling was employed to ensure maximum 
variation in recruitment of GPs with a broad range of 
experience, practising in both urban and rural practices 
and providing care for patients from diverse social and 
cultural backgrounds.25 Recruitment was via a network 
of GP tutors affiliated with the ULEARN- GP network, 
a nationally represented network of GP practices.26 
GPs were contacted by email and invited to participate 
(N=20). Those who agreed to participate were sent infor-
mation packs, which included a letter of introduction, 
information leaflet and a consent form.
Data collection was undertaken from July 2019 to 
March 2020. Interviews were guided by a pilot- tested 
structured interview consisting of open- ended questions 
and probes developed after a preliminary review of the 
literature and through discussion with the research team 
which included GPs (see online supplemental table 1). 
GPs were asked to discuss their experiences of depre-
scribing antidepressants in general practice.
Interviews took place at a time and venue that suited 
the GP. Before the interviews began, participants had 
time to ask questions about the study and consider partic-
ipation prior to giving written consent. All interviews were 
recorded digitally with consent, lasted 20–60 min (average 
length of 28 min) and were conducted by two researchers 
(PG and JG), both graduate entry medical students 
under the supervision of DK. In addition, following each 
interview, the researcher reflected on data collection 
and documented brief field notes to capture contextual 
details, summarise main ideas, identify emerging codes as 
data collection and analysis proceeded in parallel. Data 
collection ceased after 10 interviews were conducted as 
data saturation appeared to occur initially after eight 
interviews with the final two interviews serving to test the 
evolving themes. As no new codes were identified in the 
final two interviews, we concluded data saturation had 
occurred.
All interview audio files and transcriptions were stored 
in compliance with the Irish General Data Protection 
Regulations. Interviews were transcribed verbatim by one 
member of the research team, anonymised and accuracy 
confirmed by reading transcriptions while listening to 
original interviews. Braun and Clarke’s (2013) frame-
work informed thematic data analysis.27 Codes and 
themes iteratively derived from the data were discussed 
and agreed by authors (DK, JG, MN) who met biweekly to 
review and compare summaries. Where we disagreed on 
meaning, we revisited the original interview transcripts 
to seek clarification and to attain a consensus on inter-
pretation. Disconfirming evidence was identified and 
presented in the final analysis. Rigour was ensured by 
methodological coherence and sampling adequacy and 
an iterative process of data analysis which involved three 
researchers (DK, JG, MN) in coding and confirmation 
of themes. Furthermore, two general practitioners (PH 
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Table 1 Participant demographic details
Years of experience Practice type Gender
<5 years (n=3) Urban (n=6) Female (n=3)
5–10 years (n=4) Rural (n=3) Male (n=7)
>25 years (n=3) Both (n=1)
Table 2 Overview of themes and subthemes
Shared decision- making  ► Shared decision- making
Personalised therapy  ► Medical factors
 ► Psychosocial factors
Medication- tapering toolkit  ► Tapering regimen
 ► Facilitators to deprescribing
Health service factors  ► Availability of psychological services
 ► Access to psychiatry
 ► Gaps in care
Concerns around tapering  ► Fear of relapse
 ► Withdrawal symptoms
and LG) participated in a reflective session to review and 
refine themes and to ensure that the findings captured 
a GP perspective. Thematic development is presented in 
online supplemental table 2.
reSultS
Demographic details of GPs interviewed (n=10) are 
provided in table 1.
The data were categorised into five themes: shared 
decision- making; personalised therapy; medication- 
tapering toolkit; health service factors and concerns 
around tapering (table 2).
theme 1: shared decision-making
This theme explores the factors that influence GPs’ deci-
sions around discontinuing antidepressants.
Participants identified that a shared decision- making 
process was ideal and that, where possible, decisions to 
discontinue antidepressants were made in conjunction 
with patients. While in some cases patients took the 
lead in requesting a consultation to begin the process of 
discontinuing antidepressants, in the majority of cases it 
was the GP who opened the conversation around depre-
scribing: ‘My decision to stop the medication is usually 
very much in conjunction with the patient and sometimes 
led by them’ (GP1).
GPs revisited the conversation around deprescribing at 
a later time in response to patients who were reluctant to 
discontinue. GPs also acknowledged the ‘nebulous nature 
of depression’ and that many of the patients had complex 
reasons for ‘not wanting to rock the boat’ (GP6).
If someone really doesn't want to come off, certainly 
I think that it’s something you revisit when you see 
them but you're not going to force somebody off a 
medication if they feel that it is doing them some 
good and they want to stay on it. (GP7)
All participants recognised that patients some-
times discontinue antidepressants without medical 
guidance. GPs expressed concerns about the risk of 
relapse for patients who engaged in antidepressant 
self- discontinuation.
A lot of patients would come back in and you might 
see them in six months’ time and it emerges that they 
have taken themselves off. (GP9)
‘They come in and they've relapsed because they’ve just 
stopped it themselves because they felt good, I’m doing 
great and l don’t need these anymore. So that can be I 
suppose patient led deprescribing’ (GP4). In complex 
cases, the decision would be made by or in conjunction 
with a multidisciplinary team particularly where patients 
experienced severe or enduring mental health conditions.
Participants often identified the importance of having 
access to advise from colleagues in psychiatry for patients 
with complex presentations, severe and long- term illness, 
an initial diagnosis of refractory depression, co- occurring 
mental health conditions, substance dependency and for 
patients who had suicidal ideation or intent.
I think it’s really important that we have the safety 
component of secondary care backup if needed. 
That you know there is a pathway there. That you can 
speak with somebody in psychiatric care for advice if 
needed; that you can refer someone quickly if need-
ed. (GP5)
Some participants suggested that the decision to discon-
tinue antidepressants was the responsibility of the psychi-
atrist in cases where the patient was under the care of the 
mental health team. Participants frequently identified the 
challenges of deprescribing for patients who are on long- 
term antidepressants which were originally prescribed by 
the psychiatrist but who are no longer under the care of 
the psychiatrist.
They are particularly concerned about stopping it be-
cause they’ll say well the psychiatrist started the tab-
let, why are you stopping it and you're, what happens 
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if this is the wrong course and all that. So they're, an 
even harder group to try and manage: when they’ve 
been started by someone else many years ago. (GP4)
theme 2: personalised therapy
This theme describes the context that influences GPs’ 
decision- making process around deprescribing. The 
following two subthemes were identified as influencing 
discontinuation and patient outcomes: medical factors 
and psychosocial factors.
Medical factors
The length of time the patient was taking antidepressants 
is one factor that GPs considered when deciding about 
deprescribing. Generally, GPs had their own protocols 
in relation to length of time that patients should stay on 
antidepressants and this varied between participants from 
6 months to 1 year. Decisions around length of treatment 
were based on individual patient needs such as patient 
age and whether it was a first episode or recurrence of 
depression.
A young girl in her twenties. I would leave them on 
it for at least a year… If you've got an elderly person 
who’s got, a lot going on, then I would tend to leave 
them. (GP3)
For a recurrent depressive episode … it would be a 
longer course of treatment…. If they had particularly 
bad episodes in the past, then they might need long 
term antidepressants. (GP10)
All participants took into account the patients’ func-
tional response to treatment, when deciding to discon-
tinue antidepressant medication.
Are they functioning better within their life and their 
family and their work context. Whether they feel that 
they are fully recovered. That they feel that they've 
been well for a significant number of months. (GP1)
Sometimes the decision was to leave patients with 
chronic depression on medication.
And then very elderly patients too who have a lot 
of co- morbid illness, chronic disease…. People who 
have a history of drug addiction, a history of alcohol-
ism. (GP10)
Psychosocial factors
When making decisions about the timing of antide-
pressant discontinuation, participants considered the 
person’s current life circumstances such as changes in 
employment, upcoming events and support networks.
So we can look back at periods of stability, but then 
also look forward to any events coming up that may 
be stressful events. But if they are saying in the next 
three to four months I don't expect anything unusu-
al. I don't have any big family events or not changing 
jobs. Then this might be a time where we might look 
at reducing the medication. (GP4)
theme 3: medication-tapering toolkit
This theme explores the informal tapering programmes 
that GPs implemented to reduce withdrawal symptoms 
and increase the chances of success under two subthemes: 
tapering regimen and facilitators to deprescribing.
Tapering regimen
GPs viewed deprescribing as their role, recognised 
the opportunities for reviewing ‘patients on multiple 
occasions over a period’ (GP1) and were confident 
in supporting the majority of patients to discontinue 
antidepressants.
If it’s a mild to moderate depression, uncomplicated 
depression or perhaps that first episode of depression 
then I would be very happy to prescribe and depre-
scribe. GP1
Participants developed their own individual tapering 
regimen for discontinuing antidepressants which was 
typically informed by a combination of professional expe-
rience, knowledge shared by colleagues and the National 
Institute for Health and Care Excellence guidelines.17
The process of tapering medication was dependent 
on type of antidepressant, dose, length of treatment, 
patient’s response to a reduction in the dose of medica-
tion and involved a ‘gradual, soft deprescribing’ (GP6) 
regime. Deprescribing was frequently described as ‘low 
and slow’ (GP1).
Really do it very gradually and keep them under re-
view, make sure that their mood is not suffering or 
their symptoms are not recurring and that they're not 
having any physical symptoms related to them to deal 
with the withdrawal of antidepressants. (GP1)
Participants emphasised the importance of non- 
pharmacological approaches to depression which may 
include lifestyle advice such as ‘avoiding alcohol, avoiding 
drugs, taking exercise’ (GP9).
In general, GPs did not provide any other medica-
tion during the tapering process as they did not see the 
benefit of adjunct medicines as helping with withdrawal 
symptoms.
I don’t introduce any other drugs. There are no buf-
fers for it. (GP2)
Facilitators to deprescribing
This subtheme explores the variety of factors that GPs 
perceived currently and in the future would support 
them in their role of deprescribing.
The majority of participants identified some value in 
having standardised clinical guidelines to assist them to 
provide evidence- based care for deprescribing. Addi-
tional advice on when and how to deprescribe was partic-
ularly welcome to guide decisions around complex cases 
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and where patients were on long- term treatment, had 
chronic illness, comorbidities and polypharmacy.
I think guidelines could be of potential use. But I 
think that use would be very limited unless people 
in the community such as pharmacists and GPs had 
major input into the designing of those guidelines. 
(GP5)
However, some participants did not see the value of 
having guidelines specifically on deprescribing.
Personally I’m not sure what a guide would do. I 
mean there is nobody really reads these guides any-
way. (GP2)
Other facilitators included education on deprescribing, 
audit tools, and inbuilt prompts on prescribing software 
to review a patient’s medication and patient information 
on deprescribing.
Repeat prescription systems, maybe a notice when 
you’re a printing them off, not even specific to SSRIs 
but some sort of a notice like have you taken the op-
portunity to deprescribe at this time. (GP2)
A participant then suggested that repeat prescriptions 
should not be available for antidepressants.
Practice policy of not having repeat prescriptions. 
They are only prescribed every time you see the doc-
tor. You can’t just rock up and ask for a refill or repeat 
prescription without seeing a healthcare professional 
either a nurse or a doctor beforehand. I think if those 
sort of strategies are in place, then the deprescribing 
doesn't become an issue as it’s done appropriately. 
(GP10)
theme 4: health service factors
This theme covers health service factors that influence the 
management of depression by GPs and explores access to 
psychological services, psychiatry and gaps in care.
Availability of psychological services
GPs acknowledged their therapeutic role in listening to 
and counselling patients, however they recognised their 
limitations and valued the importance of having referral 
options for psychological interventions. ‘In a lot of cases 
we don't have the skills. And that’s really important as a 
doctor, right, is to know your limitations’ (GP3).
All participants identified the importance of evidence- 
based adjunct psychological interventions to support the 
deprescribing process such as cognitive therapy, counsel-
ling and talk therapy.
‘It would be great to use those psychological supports 
for that (deprescribing SSRIs)’. A lack of access to psycho-
logical services was identified as a challenge.
There are no cognitive services freely available. People 
can pay for them. There are none freely available. I’m 
not going to get priority if I say I want to stop a SSRI 
and I want you to provide cognitive support. (GP2)
Access to psychiatry
GPs valued the opportunity to consult with colleagues in 
the psychiatric services and this was difficult to access for 
some participants.
There is a whole bunch of people falling in between 
the cracks between us and secondary care services, 
because there are no services there. (GP9)
Gaps in care
Another subtheme that influenced patient outcomes is 
gaps in care. Split care was sometimes a feature of mental 
health, where a patient sees another GP rather than their 
own GP.
In the busyness of our everyday work, they might 
leave in one prescriptions for 6 months and the next 
prescription for 6 months and no one is keeping 
an eye on their file. And if you are particularly in a 
multi- partner practice, you may fall in between lots of 
different stools. Like a collusion of institutional ano-
nymity. So you kind of get lost in the system. (GP6)
All participants spoke about the importance of having 
time to therapeutically engage with patients and support 
them through the discontinuation process. Time was the 
most common resource constraint identified by GPs.
I think people can benefit a lot if a doctor has time to 
talk to them about it. But often you are very rushed in 
general practice. You have 10- minute consultations. 
Obviously, you will always give someone the time they 
need. But they are aware that you are under time re-
strictions. (GP8)
GPs also acknowledged that some patients may be left 
on antidepressants for too long due to a lack of review or 
that antidepressants may be prescribed for mild depres-
sion where they are not warranted.
There are always lots of factors around decisions. But 
I think often patients do probably stay on antidepres-
sants a bit longer than they should possibly or stay on 
medications that perhaps aren’t really helping their 
symptoms. So I think we do need to really try and be 
that better by following those patients up and making 
decisions. (GP1)
theme 5: concerns around tapering
This theme explores participants’ concerns around 
tapering antidepressant medication which were primarily 
focused on the patients’ and GPs’ fears of relapse and with-
drawal symptoms. Fears around relapse centred around 
the impact this decision would have for the patient and 
their family.
If someone relapses during the tapering period, it 
can be quite difficult to know. They can see it as quite 
a negative thing, that they will be on these for life. 
(GP4)
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Participants emphasised that discontinuing antidepres-
sants may not be the right decision for some patients and 
when patients relapsed, it left GPs questioning the conse-
quences of their decisions for the patient.
If someone rebounds when you drop them from a 
high dose to a medium dose they are now poorly. You 
might sit on that for a week or two and see does it 
ameliorate but you may have made the wrong deci-
sion and now caused a medical problem for some-




The findings of this study reveal the multitude of factors 
that shape GPs’ decision- making on antidepressant 
deprescribing, providing information for clinicians and 
policymakers that may optimise antidepressant discon-
tinuation in primary care. GPs felt confident in depre-
scribing antidepressants for patients receiving treatment 
for mild- to- moderate depression. However, hesitancy 
around considering deprescribing was expressed when 
reviewing patients with long- term, recurrent depression, 
older patients and patients with comorbidities. Access 
to evidence- based psychological therapies, guidelines, 
information on rates of relapse, patient information on 
discontinuing antidepressants and reminder prompts to 
deprescribe on GP- prescribing software were suggested 
to optimise appropriate antidepressant discontinuation.
Comparison with the literature
We found the decision to discontinue antidepressants 
usually required detailed conversations between GPs and 
their patients, either prompted by the GP or patient. 
Time was sometimes a barrier to these conversations 
being done proactively. Patient preference for involve-
ment in decision- making varies and studies have found a 
substantial number of patients preferred less involvement 
in medical decision- making than perceived.28 A study by 
Malpass et al29 found that GPs sometimes assigned patients 
with ownership of making decisions regarding antide-
pressant treatment specifically. They concluded that 
patients may have what they termed ‘unvoiced agendas’ 
within the complexity of a shared decision- making model 
and caution that in some cases patients’ do not voice 
their needs around continuation, deteriorating illness 
and discontinuation of antidepressants. There is limited 
evidence of previous research among GPs with one 
study reporting that some GPs expect patients to contact 
their practitioner when they wish to make changes to 
or discontinue their antidepressant.22 These findings 
caution against assuming the patient will initiate a discus-
sion about discontinuation and suggest that patients want 
support and guidance for this process from their GP.
GPs in this study described a shared decision- making 
process that involved a combination of familiarity and 
rapport with the patient and knowledge of their social 
circumstances (family, job, significant relationships) 
coupled with their own clinical experiences with depres-
sion and antidepressants. In our study, GPs acknowledge 
the complexity of contextual factors that influence the 
trajectory of depression and discontinuation of antide-
pressants and this has been described elsewhere.30 31 
The perceived cause of depression has been reported as 
both a barrier and facilitator to deprescribing antidepres-
sants. Suggesting antidepressants correct a biochemical 
deficiency is likely to encourage a belief in the need for 
life- long use among patients,22 32 33 while seasonal and 
life circumstances as triggers for depressive episodes can 
facilitate discontinuation.34
Associations between depression and ageing are well 
documented.30 35 In our study, GPs stated that older 
patients may have to remain on antidepressants long 
term. More generally, it is a common perception that an 
accepted part of ageing is to become depressed.36 More 
recent studies are emerging that negative ageing percep-
tions predict the persistence of depression and anxiety.37 
The low expectations for recovery among this cohort may 
be a modifiable factor in GPs and patients that may lend 
itself to interventions targeting recovery and antidepres-
sant discontinuation. Information on the rate of relapse 
after antidepressant discontinuation in this cohort would 
be useful.
Avoiding destabilisation of a patient during and 
following discontinuation was a primary concern for 
GPs in our study. Fear of relapse has been reported in 
the literature among both GPs and patients.21 30 38 Rates 
of relapse during discontinuation are currently unavail-
able for different patient groups, with a recent system-
atic review reporting rates of between 15% and 80% for 
various interventions.39 Information on rates of relapse 
during discontinuation and among those who stay on 
antidepressants long term would be useful to inform 
clinical decisions. Some evidence suggests that cogni-
tive–behavioural therapy or mindfulness- based cognitive 
therapy can help patients discontinue antidepressants 
without increasing the risk of relapse/recurrence.39–41 
Limited access to psychological services in the Irish 
healthcare system was highlighted by GPs. Fractured care 
such as split care between psychiatrists and GPs or consul-
tations with multiple GPs were identified as barriers to 
discontinuing antidepressants. This is a persistent feature 
of mental healthcare in Ireland, which liaison psychiatry 
models partly address,42 although more resources and 
research are needed to expand collaborations.43
Regarding drug choice and dose, prescribing was influ-
enced by GP’s prior clinical experience and SSRIs were 
viewed as an effective and safe choice echoing the litera-
ture.38 44 GPs were in agreement that tapering slowly was 
the preferred way to reduce and eventually stop an anti-
depressant medication. Prescribing practices were devel-
oped through seeking advice from colleagues in general 
practice and psychiatry experience, and by exploring 
patient preferences. Prescribers viewed antidepressants 
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as one component of a multifaceted approach in which 
GPs valued their therapeutic function as listener, coun-
sellor and facilitator. These findings are in keeping with 
the literature.44 The use of subtherapeutic doses may be 
a helpful dose- reduction strategy45 but is not currently in 
line with current recommendations and requires further 
research to determine feasibility and effectiveness among 
patients.
Implications to research and practice
Negative expectations and experiences of ageing can 
reinforce perceptions that antidepressants are long- term 
treatments, and that discontinuation is thus undesirable. 
This needs to be countered by appropriate patient and 
practitioner education. GPs require access to nationally 
integrated guidance and care pathways on antidepressant 
discontinuation with a particular focus on supporting 
deprescribing for older patients and patients on long- 
term antidepressants. Treatment plans and formal prac-
tice protocols that include discontinuation and scheduled 
medication review rather than current informal 
approaches may support optimal antidepressant discon-
tinuation. Access to evidence- based psychological inter-
ventions, patient leaflets and web information sources 
may prevent patient self- discontinuation and relapse. 
Audits and inbuilt prompts on GP- prescribing software 
and on pharmacy systems to review a patient’s medication 
may support antidepressant discontinuation. Studies that 
examine rates of relapse during discontinuation among 
older patients and those who stay on antidepressants long 
term would be useful to inform clinical decisions.
Strengths and weaknesses
This study, the first of its kind in an Irish context, employed 
robust and transparent methods to conduct and report 
study findings. A strength of this study is recruitment of 
a diverse sample of GPs, with experience ranging from 
less than 5 years to more than 25 years, practising in a 
range of urban and rural population practices. A detailed 
description of context, methods, and findings facilitates 
judgement of transferability and validity. Multiple coders 
from different professional backgrounds supported a 
more complex understanding of the phenomenon and a 
greater reflexivity in the data analysis. However, findings 
should be interpreted in the context of study limitations 
where the sample of GPs was small and affiliated to one 
country. Furthermore, participants were from a network 
of GP tutors affiliated with the ULEARN- GP network and 
who, because of their role in education, may have an 
enhanced knowledge of deprescribing. While data satura-
tion was reached, theoretical saturation and theory devel-
opment were not within the scope of the study.
COnCluSIOn
This paper explores factors involved in GP decisions 
behind deprescribing antidepressants. The findings 
suggest that multiple strategies including scheduled 
medication review, detailed guidance on tapering, audits, 
inbuilt prompts on GP- prescribing software and access to 
evidence- based psychological interventions and patient 
information sources may support optimal antidepressant 
discontinuation. Further research is required to docu-
ment the risk of relapse when antidepressants are discon-
tinued, particularly for older patients with multimorbidity 
and patients on long- term antidepressant therapy.
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